To include your compound in the COVID-19 Resource Center, submit it here.

BHCG-VAC: Phase II discontinued

Celldex disclosed in its 2Q11 earnings that in June it discontinued an open-label, U.S. Phase II trial comparing neoadjuvant therapy

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE